These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The blind men and the AML elephant: can we feel the progress? Tauro S Blood Cancer J; 2016 May; 6(5):e424. PubMed ID: 27176800 [TBL] [Abstract][Full Text] [Related]
9. Induction therapy in acute myeloid leukemia: Is it time to put aside standard 3 + 7? Ferrara F; Vitagliano O Hematol Oncol; 2019 Dec; 37(5):558-563. PubMed ID: 30938858 [TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia. Stone RM; O'Donnell MR; Sekeres MA Hematology Am Soc Hematol Educ Program; 2004; ():98-117. PubMed ID: 15561679 [TBL] [Abstract][Full Text] [Related]
11. Future prospects of therapeutic clinical trials in acute myeloid leukemia. Khan M; Mansoor AE; Kadia TM Future Oncol; 2017 Mar; 13(6):523-535. PubMed ID: 27771959 [TBL] [Abstract][Full Text] [Related]
12. Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. Chen KTJ; Gilabert-Oriol R; Bally MB; Leung AWY Pharm Res; 2019 Jun; 36(9):125. PubMed ID: 31236772 [TBL] [Abstract][Full Text] [Related]
13. What Is the Optimal Induction Therapy for Younger Fit Patients With AML? Fernandez HF Curr Hematol Malig Rep; 2016 Oct; 11(5):327-32. PubMed ID: 27475430 [TBL] [Abstract][Full Text] [Related]
15. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study]. Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899 [TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia. Rubnitz JE; Gibson B; Smith FO Pediatr Clin North Am; 2008 Feb; 55(1):21-51, ix. PubMed ID: 18242314 [TBL] [Abstract][Full Text] [Related]
17. Precision therapy for acute myeloid leukemia. Yang X; Wang J J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553 [TBL] [Abstract][Full Text] [Related]
18. New trends in the standard of care for initial therapy of acute myeloid leukemia. Fernandez HF Hematology Am Soc Hematol Educ Program; 2010; 2010():56-61. PubMed ID: 21239771 [TBL] [Abstract][Full Text] [Related]
19. Novel approaches to the treatment of acute myeloid leukemia. Roboz GJ Hematology Am Soc Hematol Educ Program; 2011; 2011():43-50. PubMed ID: 22160011 [TBL] [Abstract][Full Text] [Related]
20. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives. Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]